The aims of the current study are to explore (1) whether the novel PKD inhibitors block NF-κB activation in experimental pancreatitis models, and (2) whether suppressing of NF-κB activation by the PKD inhibitors is associated with attenuation of inflammatory response and severity of pancreatitis, as well as (3) the therapeutic benefit of the PKD inhibitors administered after induction of the pancreatitis. The gene discussed is PRKD1; the disease is pancreatitis.